ArticleCureus2026
Utility of Synovial Alpha Defensin Lateral Flow Test in Diagnosing Septic Arthritis in Native Knees.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeptic arthritis of native joints requires prompt diagnosis to prevent joint destruction and sepsis. Traditional diagnostic methods, such as synovial fluid culture and cell counts, are time-consuming and can be unreliable. The Synovasure® Alpha Defensin Lateral Flow Test (Zimmer Biomet, Claymont, DE, USA) detects alpha defensin in synovial fluid and is well-established for diagnosing periprosthetic joint infections. However, its diagnostic value in native joints remains insufficiently studied.
methodsThis prospective cohort study enrolled 25 adults presenting with suspected septic arthritis of the knee. Patients were excluded if they had prior knee arthroplasty or orthopedic implants. Demographics, comorbidities, vitals, and lab values were collected. Patients who tested positive for alpha defensin on aspirated synovial fluid were compared to those who tested negative. Infection was defined as a positive synovial culture, while gout was defined as positive synovial crystals. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
resultsNineteen patients tested positive for alpha defensin, of whom four had culture-confirmed septic arthritis. All six alpha defensin test-negative patients had negative cultures. The test demonstrated a sensitivity of 100% (CI: 39%-100%), specificity of 29% (CI: 11%-52%), PPV of 21% (CI: 16%-25%), and NPV of 100% (CI: 54%-100%). Demographics, comorbidities, and serum inflammatory markers were similar between test-positive and test-negative groups. Alpha defensin test-positive patients had a significantly higher synovial polymorphonuclear neutrophil (PMN) percentage (p<0.001). All nine patients with positive synovial crystals tested positive (p=0.04). DISCUSSION: The high sensitivity and NPV of the Synovasure® Alpha Defensin Lateral Flow Test (Zimmer Biomet) demonstrate its potential utility to rapidly rule out septic arthritis in native knees. However, the test's low specificity warrants caution, as false-positive results may occur with noninfectious inflammatory processes. While the rapid turnaround may aid in early triage and exclusion of infection, confirmatory evaluation with synovial culture remains essential to prevent misdiagnosis and overtreatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.